Circulating tumor cells: A novel prognostic factor for newly diagnosed metastatic breast cancer

Journal of Clinical Oncology

Volumn 23, Issue 7, 2005, Pages 1420-1430

  Cristofanilli, Massimo ^a   Hayes, Daniel F ^a   Budd, G Thomas ^a   Ellis, Mathew J ^a   Stopeck, Alison ^a   Reuben, James M ^a   Doyle, Gerald V ^a   Matera, Jeri ^a   Allard, W Jeffrey ^a   Miller, M Craig ^a   Fritsche, Herbert A ^a   Hortobagyi, Gabriel N ^a   Terstappen, Leon W M M ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; SEX HORMONE; TRASTUZUMAB;

ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DISEASE COURSE; FEMALE; FOLLOW UP; HUMAN; IMAGING SYSTEM; IMMUNOMAGNETIC SEPARATION; MAJOR CLINICAL STUDY; MULTICENTER STUDY; OVERALL SURVIVAL; PALLIATIVE THERAPY; PRIORITY JOURNAL; PROGNOSIS; QUALITY OF LIFE; TUMOR CELL; BREAST TUMOR; METASTASIS; MIDDLE AGED; MORTALITY; PATHOLOGY; PROSPECTIVE STUDY; SURVIVAL RATE; TUMOR EMBOLISM;

BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM CIRCULATING CELLS; NEOPLASM METASTASIS; PROGNOSIS; PROSPECTIVE STUDIES; SURVIVAL RATE;

EID: 20144385756     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.08.140     Document Type: Article

References (22)

1. Ellis M, Hayes DF, Lippman ME: Treatment of metastatic disease, in Harris J, Lippman M, Morrow M, et al (eds). Diseases of the Breast (ed 2). Philadelphia, PA, Lippincott-Raven, 2000, pp 749-799
2. Greenberg PA, Hortobagyi GN, Smith TL, et al: Long-term follow-up of patients with complete remission following combination chemotherapy for metastatic breast cancer. J Clin Oncol 14:2197-2205, 1996
3. Nieto Y, Cagnoni PJ, Shpall EJ, et al: Phase II trial of high-dose chemotherapy with autologous stem cell transplant for stage IV breast cancer with minimal metastatic disease. Clin Cancer Res 5:1731-1737, 1999
4. Rivera E, Holmes FA, Buzdar AU, et al: Fluorouracil, doxorubicin, and cyclophosphamide followed by tamoxifen as adjuvant treatment for patients with stage IV breast cancer who have no evidence of disease. Breast J 8:2-9, 2002
5. Swenerton KD, Legha SS, Smith L, et al: Prognostic factors in metastatic breast cancer treated with combination chemotherapy. Cancer Res 39:1552-1562, 1979
6. Hortobagyi GN, Smith TL, Legha SS, et al: Multivariate analysis of prognostic factors in metastatic breast cancer. J Clin Oncol 1:776-786, 1983
7. Beitsch PD, Clifford E: Detection of carcinoma cells in the blood of breast cancer patients. Am J Surg 180:446-449, 2000
8. Fehm T, Sagalowsky A, Clifford E, et al: Cytogenetic evidence that circulating epithelial cells in patients with carcinoma are malignant. Clin Cancer Res 8:2073-2084, 2002
9. Gaforio JJ, Serrano MJ, Sanchez-Rovira P, et al: Detection of breast cancer cells in the peripheral blood is positively correlated with estrogen-receptor status and predicts poor prognosis. Int J Cancer 107:984-990, 2003
10. Austrup F, Uciechowski P, Eder C, et al: Prognostic value of genomic alterations in minimal residual cancer cells purified from the blood of breast cancer patients. Br J Cancer 83:1664-1673, 2000
11. Terstappen LWMM, Rao C, Gross S, et al: Peripheral blood tumor cell load reflects the clinical activity of the disease in patients with carcinoma of the breast. Int J Oncol 17:573-578, 2000
12. Ashworth TR: A case of cancer in which cells similar to those in the tumors were seen in the blood after death. Aust Med J 14:146-147, 1869
13. Carey RW, Taft PD, Bennett JM, et al: Carcinocythemia (carcinoma cell leukemia): An acute leukemia-like picture due to metastatic carcinoma cells. Am J Med 60:273-278, 1976
14. Myerowitz RL, Edwards PA, Sartiano GP: Carcinocythemia (carcinoma cell leukemia) due to metastatic carcinoma of the breast: Report of a case. Cancer 40:3107-3111, 1977
15. Gallivan MV, Lokich JJ: Carcinocythemia (carcinoma cell leukemia): Report of two cases with English literature review. Cancer 53:1100-1102, 1984
16. Cristofanilli M, Budd GT, Ellis M, et al: Circulating tumor cells predict progression free survival and overall survival in metastatic breast cancer. N Engl J Med 351:781-791, 2004
17. Allard WJ, Matera J, Miller MC, et al: Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with non-malignant diseases. Clin Cancer Res 15:6897-6904, 2004
18. Momburg F, Moldenhauer G, Hammerling GJ, et al: Immunohistochemical study of the expression of a Mr 34,000 human epithelium specific surface glycoprotein in normal and malignant tissues. Cancer Res 47:2883-2891, 1987
19. Kagan M, Howard D, Bendele T, et al: Circulating tumor cells as cancer markers, a sample preparation and analysis system, in Diamandis EP, Fritsche HA, Lilja H, et al (eds): Tumor Markers: Physiology, Pathobiology, Technology and Clinical Applications. Washington, DC, American Association for Clinical Chemistry Press, 2002, pp 495-498
20. Buzdar A, Vergote I, Sainsbury R: The impact of hormone receptor status on the clinical efficacy of the new-generation aromatase inhibitors: A review of data from first-line metastatic disease trials in postmenopausal women. Breast J 10:211-217, 2004
21. Bonneterre J, Thurlimann B, Robertson JF, et al: Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: Results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 18:3748-3757, 2000
22. Mouridsen H, Gershanovich M, Sun Y, et al: Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women: Analysis of survival and update of efficacy from the International Letrozole Breast Cancer Group. J Clin Oncol 21:2101-2109, 2003